1. Home
  2. YMAB
  3. YMAB News

Latest Y-mAbs Therapeutics Inc. (YMAB) News on August 8, 2025

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
YMAB

Simply Wall St.

2 months ago

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

YMAB

MT Newswires

2 months ago

Oppenheimer Adjusts Price Target on Y-mAbs Therapeutics to $15 From $20, Maintains Outperform Rating

YMAB

MT Newswires

2 months ago

Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
YMAB

GlobeNewswire

2 months ago

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
YMAB

Insider Monkey

2 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
YMAB

GlobeNewswire

2 months ago

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations
YMAB

Simply Wall St.

3 months ago

Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations

Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
YMAB

TipRanks

3 months ago

Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension

YMAB

MT Newswires

3 months ago

Oppenheimer Adjusts Y-mAbs Therapeutics Price Target to $20 From $21, Maintains Outperform Rating

YMAB

MT Newswires

3 months ago

Truist Securities Adjusts Y-mAbs Therapeutics Price Target to $14 From $18, Maintains Buy Rating

YMAB

GuruFocus.com

3 months ago

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

YMAB

Thomson Reuters StreetEvents

3 months ago

Q1 2025 Y-mAbs Therapeutics Inc Earnings Call

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
YMAB

Zacks

3 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
YMAB

GlobeNewswire

3 months ago

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
YMAB

GlobeNewswire

3 months ago

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

Earnings To Watch: Y-mAbs Therapeutics Inc (YMAB) Reports Q1 2025 Result
YMAB

GuruFocus.com

3 months ago

Earnings To Watch: Y-mAbs Therapeutics Inc (YMAB) Reports Q1 2025 Result

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
YMAB

GlobeNewswire

3 months ago

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
YMAB

GlobeNewswire

3 months ago

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
YMAB

Zacks

3 months ago

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
YMAB

Zacks

3 months ago

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
YMAB

GlobeNewswire

3 months ago

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures
YMAB

Simply Wall St.

3 months ago

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
YMAB

GlobeNewswire

3 months ago

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma

YMAB

MT Newswires

4 months ago

Top Premarket Decliners

Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates
YMAB

Simply Wall St.

5 months ago

Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates

YMAB

MT Newswires

5 months ago

Oppenheimer Adjusts Y-mAbs Therapeutics Price Target to $21 From $23, Maintains Outperform Rating

YMAB

MT Newswires

5 months ago

Truist Cuts Price Target on Y-mAbs Therapeutics to $18 From $21, Keeps Buy Rating

YMAB

GuruFocus.com

5 months ago

Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ...

YMAB

Thomson Reuters StreetEvents

5 months ago

Q4 2024 Y-mAbs Therapeutics Inc Earnings Call

YMAB

MT Newswires

5 months ago

Wedbush Cuts Price Target on Y-mAbs Therapeutics to $21 From $23, Keeps Outperform Rating

Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years ago
YMAB

Simply Wall St.

5 months ago

Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years ago

Y-mAbs announces publication of Phase 2 interim results on naxitamab
YMAB

TipRanks

5 months ago

Y-mAbs announces publication of Phase 2 interim results on naxitamab

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates
YMAB

Zacks

5 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
YMAB

GlobeNewswire

5 months ago

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
YMAB

GlobeNewswire

5 months ago

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

YMAB

GuruFocus.com

5 months ago

Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Report Preview: What To Look For

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
YMAB

Zacks

5 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
YMAB

GlobeNewswire

6 months ago

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference
YMAB

GlobeNewswire

6 months ago

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
YMAB

Zacks

6 months ago

YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
YMAB

Zacks

6 months ago

YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
YMAB

GlobeNewswire

6 months ago

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

Y-mAbs Therapeutics Announces Strategic Business Realignment
YMAB

TipRanks

7 months ago

Y-mAbs Therapeutics Announces Strategic Business Realignment

YMAB

MT Newswires

7 months ago

Y-mAbs Therapeutics Establishing Two New Business Units, Reports 2024 Preliminary Net Revenue

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities
YMAB

GlobeNewswire

7 months ago

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
YMAB

GlobeNewswire

7 months ago

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

Y-mAbs Provides Strategic Business Update and 2025 Priorities
YMAB

GlobeNewswire

7 months ago

Y-mAbs Provides Strategic Business Update and 2025 Priorities

Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA
YMAB

TipRanks

7 months ago

Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA

YMAB

MT Newswires

7 months ago

BofA Securities Adjusts Price Target on Y-mAbs Therapeutics to $14 From $17, Maintains Neutral Rating

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
YMAB

GlobeNewswire

8 months ago

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely
YMAB

Simply Wall St.

8 months ago

We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely

Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
YMAB

TipRanks

8 months ago

Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
YMAB

GlobeNewswire

8 months ago

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

YMAB

MT Newswires

8 months ago

Brookline Capital Initiates Y-mAbs Therapeutics at Buy With $17 Price Target

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
YMAB

GlobeNewswire

8 months ago

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

YMAB

MT Newswires

9 months ago

Oppenheimer Initiates Coverage on Y-mAbs Therapeutics With Outperform Rating, $23 Price Target

Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth
YMAB

Simply Wall St.

9 months ago

Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth

YMAB

GuruFocus.com

9 months ago

Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
YMAB

Zacks

9 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
YMAB

GlobeNewswire

9 months ago

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings
YMAB

GuruFocus.com

9 months ago

What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings

Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?
YMAB

Zacks

9 months ago

Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
YMAB

GlobeNewswire

9 months ago

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
YMAB

Zacks

9 months ago

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
YMAB

GlobeNewswire

9 months ago

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

YMAB

GuruFocus.com

10 months ago

Y-mAbs Therapeutics Inc (YMAB) Q2 2024 Earnings Call Highlights: Revenue Growth Driven by ...

Y-mAbs to Participate in Upcoming Investor Conferences in October
YMAB

GlobeNewswire

10 months ago

Y-mAbs to Participate in Upcoming Investor Conferences in October

While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate
YMAB

Simply Wall St.

10 months ago

While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate

YMAB

MT Newswires

a year ago

Y-mAbs Therapeutics Signs Lease Deal for New Jersey Property

YMAB

MT Newswires

a year ago

Y-mAbs Therapeutics' Neuroblastoma Drug Shows Consistent Disease Control in Clinical Study

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
YMAB

GlobeNewswire

a year ago

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

Y-mAbs to Participate in Upcoming Investor Conferences in September
YMAB

GlobeNewswire

a year ago

Y-mAbs to Participate in Upcoming Investor Conferences in September

YMAB

MT Newswires

a year ago

Cantor Fitzgerald Initiates Coverage on Y-mAbs Therapeutics With Overweight Rating, $20 Price Target

Why Y-mAbs Therapeutics Stock Got Mashed on Monday
YMAB

Motley Fool

a year ago

Why Y-mAbs Therapeutics Stock Got Mashed on Monday

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates
YMAB

Zacks

a year ago

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
YMAB

GlobeNewswire

a year ago

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners’ Top Holdings Now?
YMAB

Insider Monkey

a year ago

Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners’ Top Holdings Now?

Y-mAbs to Participate in Upcoming Investor Conferences in August
YMAB

GlobeNewswire

a year ago

Y-mAbs to Participate in Upcoming Investor Conferences in August

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
YMAB

GlobeNewswire

a year ago

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
YMAB

Simply Wall St.

a year ago

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

YMAB

MT Newswires

a year ago

Y-mAbs Therapeutics Appoints Peter Pfreundschuh as CFO

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
YMAB

GlobeNewswire

a year ago

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

YMAB

MT Newswires

a year ago

Truist Initiates Y-mAbs Therapeutics at Buy With $21 Price Target, Calls Radioimmunotherapy Platform 'Undervalued'

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
YMAB

GuruFocus.com

a year ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

YMAB

Energy Global

a year ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
YMAB

USA TODAY

a year ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
YMAB

Business Wire

a year ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
YMAB

Business Wire

a year ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

SEALSQ to Launch Two New Quantum Resistant Chips
YMAB

GlobeNewswire

a year ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll
YMAB

Reuters

a year ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030
YMAB

GlobeNewswire

a year ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional investors' interest
YMAB

Simply Wall St.

a year ago

With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional investors' interest

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
YMAB

GlobeNewswire

a year ago

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
YMAB

GlobeNewswire

a year ago

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
YMAB

GlobeNewswire

a year ago

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
YMAB

GlobeNewswire

a year ago

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
YMAB

Insider Monkey

a year ago

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript

YMAB

GuruFocus.com

a year ago

Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

YMAB

Thomson Reuters StreetEvents

a year ago

Q1 2024 Y-mAbs Therapeutics Inc Earnings Call

Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates
YMAB

GuruFocus.com

a year ago

Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates

Share on Social Networks: